Whilst low-count MBL almost never progresses to CLL, significant-count MBL progresses to CLL demanding therapy in a fee of one% to two% a year. Significant-rely MBL is distinguished from Rai 0 CLL based upon if the B-mobile rely is over or below 5 × 109/L. Whilst people with both superior-count MBL and CLL Rai phase 0 are at elevated risk of bacte